Anergis, a company developing proprietary ultra-fast allergy vaccines, today reported positive long-term efficacy results with its lead compound AllerT, a novel birch pollen allergy vaccine. A total of 196 patients were enrolled in the Phase IIb follow-up, double-blind, placebo-controlled, field-based clinical trial. The trial objective was to evaluate the long-term efficacy of AllerT in patients who had participated last year in the fieldbased Phase IIb trial with AllerT. Patients evaluated this year either received a placebo, AllerT 50 μg or AllerT 100 μg 18 months before the second birch pollen season.